Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Zymeworks BC Inc.ZYME · Entity 12038 | Chief Scientific Officer | July 18, 2022 | July 19, 2022 |
| Zymeworks Inc.ZYME · Entity 4458 | Chief Scientific Officer | January 12, 2026 | January 13, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Zymeworks BC Inc.
Report date July 18, 2022 · Filed July 19, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.82 · Expires 2032-07-17 | Direct | 200,000 |
Reported balance
After 2022-07-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-07-18 · Grant · Acquired 200,000 · Balance 200,000 F1: Stock options vest as follows: (i) 25% of underlying shares on first anniversary of grant date and (ii) remainder of underlying shares in 36 equal monthly installments on last day of month following first anniversary of grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: Stock options vest as follows: (i) 25% of underlying shares on first anniversary of grant date and (ii) remainder of underlying shares in 36 equal monthly installments on last day of month following first anniversary of grant date.
Zymeworks Inc.
Report date January 12, 2026 · Filed January 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 48,497 |
Ending reported balance
After 2026-01-12 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-01-12 · Exercise / conversion · Acquired 17,666 · Balance 58,057 F1: Represents shares of common stock issued upon vesting of one third of the restricted stock units ("RSUs") granted on January 10, 2025. Row 2 · 2026-01-12 · Sale · Disposed 9,560 · Balance 48,497 F2: Represents shares of common stock sold to cover tax withholding obligations and other applicable fees in connection with the vesting of RSUs pursuant to mandatory "sell to cover" provisions contained in the Reporting Person's applicable RSU grant agreement, and does not represent a discretionary sale by the Reporting Person. The Reporting Person did not sell or otherwise dispose of any of the shares reported on this Form 4 for any reason other than to cover required taxes and fees. F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $22.49 to $23.05, inclusive. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 35,334 |
Reported balance
After 2026-01-12 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-01-12 · Exercise / conversion · Disposed 17,666 · Balance 35,334 F4: Each RSU represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock. F5: The RSUs were granted on January 10, 2025 and vest in three equal annual installments beginning on the first anniversary of grant date. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 47,000 |
Reported balance
After 2026-01-12 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-01-12 · Grant · Acquired 47,000 · Balance 47,000 F4: Each RSU represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock. F7: RSUs vest in four equal annual installments beginning on first anniversary of grant date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.16 · Expires 2036-01-11 | Direct | 70,000 |
Reported balance
After 2026-01-12 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-01-12 · Grant · Acquired 70,000 · Balance 70,000 F6: Stock options vest as follows: (i) 25% of underlying shares of common stock on first anniversary of grant date and (ii) remainder of underlying shares of common stock in 36 equal monthly installments on last day of month following first anniversary of grant date. |
| Performance Stock UnitSEC Table II · derivative / convertible security | Direct | 66,000 |
Reported balance
After 2026-01-12 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-01-12 · Grant · Acquired 66,000 · Balance 66,000 F8: Each performance restricted stock unit ("PSU") represents a contingent right to receive one share of common stock. The amount reported is the maximum number of PSUs that may be earned upon achievement of certain cumulative total shareholder return ("TSR") goals over a three-year performance period ending on January 12, 2029 (or in some cases at earlier times). Between 50% and 200% of the target number of 33,000 PSUs ("Target Number") may be earned upon achievement of such TSR goals. 50% of the Target Number may be earned upon achievement of relative TSR goals if the Company's TSR for the performance period equals or exceeds a prespecified percentile for the Nasdaq Biotech Index. The PSUs will only vest at the end of the three-year performance period if the Reporting Person's service to the Company continues through such time that the board of directors of the Company certifies the achievement of TSR goals, F9: (Continued from footnote 8) except in certain limited cases (such as if service to the Company is terminated by the Company without cause or in case of a change of control). |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of common stock issued upon vesting of one third of the restricted stock units ("RSUs") granted on January 10, 2025.
F2: Represents shares of common stock sold to cover tax withholding obligations and other applicable fees in connection with the vesting of RSUs pursuant to mandatory "sell to cover" provisions contained in the Reporting Person's applicable RSU grant agreement, and does not represent a discretionary sale by the Reporting Person. The Reporting Person did not sell or otherwise dispose of any of the shares reported on this Form 4 for any reason other than to cover required taxes and fees.
F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $22.49 to $23.05, inclusive. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F4: Each RSU represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock.
F5: The RSUs were granted on January 10, 2025 and vest in three equal annual installments beginning on the first anniversary of grant date.
F6: Stock options vest as follows: (i) 25% of underlying shares of common stock on first anniversary of grant date and (ii) remainder of underlying shares of common stock in 36 equal monthly installments on last day of month following first anniversary of grant date.
F7: RSUs vest in four equal annual installments beginning on first anniversary of grant date.
F8: Each performance restricted stock unit ("PSU") represents a contingent right to receive one share of common stock. The amount reported is the maximum number of PSUs that may be earned upon achievement of certain cumulative total shareholder return ("TSR") goals over a three-year performance period ending on January 12, 2029 (or in some cases at earlier times). Between 50% and 200% of the target number of 33,000 PSUs ("Target Number") may be earned upon achievement of such TSR goals. 50% of the Target Number may be earned upon achievement of relative TSR goals if the Company's TSR for the performance period equals or exceeds a prespecified percentile for the Nasdaq Biotech Index. The PSUs will only vest at the end of the three-year performance period if the Reporting Person's service to the Company continues through such time that the board of directors of the Company certifies the achievement of TSR goals,
F9: (Continued from footnote 8) except in certain limited cases (such as if service to the Company is terminated by the Company without cause or in case of a change of control).
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 12, 2026 Filed Jan 13, 2026 01:32 UTC | Zymeworks Inc. ZYME · Entity 4458 | GrantPerformance Stock Unit · Derivative | 66,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-010834 · ownership.xml · derivative · entry 6 Moore Paul Andrew · CIK 0001938192 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,000 Underlying: Common Stock · 66,000 shares Expires not disclosed F8 · derivative.exercise_price: Each performance restricted stock unit ("PSU") represents a contingent right to receive one share of common stock. The amount reported is the maximum number of PSUs that may be earned upon achievement of certain cumulative total shareholder return ("TSR") goals over a three-year performance period ending on January 12, 2029 (or in some cases at earlier times). Between 50% and 200% of the target number of 33,000 PSUs ("Target Number") may be earned upon achievement of such TSR goals. 50% of the Target Number may be earned upon achievement of relative TSR goals if the Company's TSR for the performance period equals or exceeds a prespecified percentile for the Nasdaq Biotech Index. The PSUs will only vest at the end of the three-year performance period if the Reporting Person's service to the Company continues through such time that the board of directors of the Company certifies the achievement of TSR goals, F9 · derivative.exercise_price: (Continued from footnote 8) except in certain limited cases (such as if service to the Company is terminated by the Company without cause or in case of a change of control). F8 · derivative.exercise_date: Each performance restricted stock unit ("PSU") represents a contingent right to receive one share of common stock. The amount reported is the maximum number of PSUs that may be earned upon achievement of certain cumulative total shareholder return ("TSR") goals over a three-year performance period ending on January 12, 2029 (or in some cases at earlier times). Between 50% and 200% of the target number of 33,000 PSUs ("Target Number") may be earned upon achievement of such TSR goals. 50% of the Target Number may be earned upon achievement of relative TSR goals if the Company's TSR for the performance period equals or exceeds a prespecified percentile for the Nasdaq Biotech Index. The PSUs will only vest at the end of the three-year performance period if the Reporting Person's service to the Company continues through such time that the board of directors of the Company certifies the achievement of TSR goals, F9 · derivative.exercise_date: (Continued from footnote 8) except in certain limited cases (such as if service to the Company is terminated by the Company without cause or in case of a change of control). F8 · derivative.expiration_date: Each performance restricted stock unit ("PSU") represents a contingent right to receive one share of common stock. The amount reported is the maximum number of PSUs that may be earned upon achievement of certain cumulative total shareholder return ("TSR") goals over a three-year performance period ending on January 12, 2029 (or in some cases at earlier times). Between 50% and 200% of the target number of 33,000 PSUs ("Target Number") may be earned upon achievement of such TSR goals. 50% of the Target Number may be earned upon achievement of relative TSR goals if the Company's TSR for the performance period equals or exceeds a prespecified percentile for the Nasdaq Biotech Index. The PSUs will only vest at the end of the three-year performance period if the Reporting Person's service to the Company continues through such time that the board of directors of the Company certifies the achievement of TSR goals, F9 · derivative.expiration_date: (Continued from footnote 8) except in certain limited cases (such as if service to the Company is terminated by the Company without cause or in case of a change of control). Read SEC document |
| January 12, 2026 Filed Jan 13, 2026 01:32 UTC | Zymeworks Inc. ZYME · Entity 4458 | GrantRestricted Stock Unit · Derivative | 47,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-010834 · ownership.xml · derivative · entry 5 Moore Paul Andrew · CIK 0001938192 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,000 Underlying: Common Stock · 47,000 shares Expires not disclosed F4 · derivative.exercise_price: Each RSU represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock. F7 · derivative.exercise_date: RSUs vest in four equal annual installments beginning on first anniversary of grant date. F7 · derivative.expiration_date: RSUs vest in four equal annual installments beginning on first anniversary of grant date. Read SEC document |
| January 12, 2026 Filed Jan 13, 2026 01:32 UTC | Zymeworks Inc. ZYME · Entity 4458 | GrantStock Option (Right to Buy) · Derivative | 70,000 | $0.00 Strike: $23.16 | $0.00 |
DisclosureSEC source: 0001193125-26-010834 · ownership.xml · derivative · entry 4 Moore Paul Andrew · CIK 0001938192 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2036-01-11 F6 · derivative.exercise_date: Stock options vest as follows: (i) 25% of underlying shares of common stock on first anniversary of grant date and (ii) remainder of underlying shares of common stock in 36 equal monthly installments on last day of month following first anniversary of grant date. Read SEC document |
| January 12, 2026 Filed Jan 13, 2026 01:32 UTC | Zymeworks Inc. ZYME · Entity 4458 | Exercise / conversionRestricted Stock Unit · Derivative | 17,666 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-010834 · ownership.xml · derivative · entry 3 Moore Paul Andrew · CIK 0001938192 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,334 Underlying: Common Stock · 17,666 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock. F5 · derivative.exercise_date: The RSUs were granted on January 10, 2025 and vest in three equal annual installments beginning on the first anniversary of grant date. F5 · derivative.expiration_date: The RSUs were granted on January 10, 2025 and vest in three equal annual installments beginning on the first anniversary of grant date. Read SEC document |
| January 12, 2026 Filed Jan 13, 2026 01:32 UTC | Zymeworks Inc. ZYME · Entity 4458 | SaleCommon Stock | 9,560 | $22.67 | $216,758.66 |
DisclosureSEC source: 0001193125-26-010834 · ownership.xml · nonDerivative · entry 2 Moore Paul Andrew · CIK 0001938192 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,497 F2 · kind: Represents shares of common stock sold to cover tax withholding obligations and other applicable fees in connection with the vesting of RSUs pursuant to mandatory "sell to cover" provisions contained in the Reporting Person's applicable RSU grant agreement, and does not represent a discretionary sale by the Reporting Person. The Reporting Person did not sell or otherwise dispose of any of the shares reported on this Form 4 for any reason other than to cover required taxes and fees. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $22.49 to $23.05, inclusive. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| January 12, 2026 Filed Jan 13, 2026 01:32 UTC | Zymeworks Inc. ZYME · Entity 4458 | Exercise / conversionCommon Stock | 17,666 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-010834 · ownership.xml · nonDerivative · entry 1 Moore Paul Andrew · CIK 0001938192 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,057 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents shares of common stock issued upon vesting of one third of the restricted stock units ("RSUs") granted on January 10, 2025. Read SEC document |
| January 05, 2026 Filed Jan 6, 2026 01:18 UTC | Zymeworks Inc. ZYME · Entity 4458 | Exercise / conversionRestricted Stock Unit · Derivative | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-003095 · ownership.xml · derivative · entry 6 Moore Paul Andrew · CIK 0001938192 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each RSU represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock. F7 · derivative.exercise_date: The RSUS were granted on January 5, 2024 and vest in three equal annual installments beginning on the first anniversary of January 5, 2024. F7 · derivative.expiration_date: The RSUS were granted on January 5, 2024 and vest in three equal annual installments beginning on the first anniversary of January 5, 2024. Read SEC document |
| January 05, 2026 Filed Jan 6, 2026 01:18 UTC | Zymeworks Inc. ZYME · Entity 4458 | Exercise / conversionRestricted Stock Unit · Derivative | 17,168 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-003095 · ownership.xml · derivative · entry 5 Moore Paul Andrew · CIK 0001938192 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,168 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each RSU represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock. F6 · derivative.exercise_date: The RSUS were granted on January 5, 2023 and vest in three equal annual installments beginning on the first anniversary of January 5, 2023. F6 · derivative.expiration_date: The RSUS were granted on January 5, 2023 and vest in three equal annual installments beginning on the first anniversary of January 5, 2023. Read SEC document |
| January 05, 2026 Filed Jan 6, 2026 01:18 UTC | Zymeworks Inc. ZYME · Entity 4458 | SaleCommon Stock | 10,821 | $25.10 | $271,573.55 |
DisclosureSEC source: 0001193125-26-003095 · ownership.xml · nonDerivative · entry 4 Moore Paul Andrew · CIK 0001938192 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,391 F2 · kind: Represents shares of common stock sold to cover tax withholding obligations and other applicable fees in connection with the vesting of RSUs pursuant to mandatory "sell to cover" provisions contained in the Reporting Person's applicable RSU grant agreement, and does not represent a discretionary sale by the Reporting Person. The Reporting Person did not sell or otherwise dispose of any of the shares reported on this Form 4 for any reason other than to cover required taxes and fees. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $24.715 to $25.84, inclusive. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| January 05, 2026 Filed Jan 6, 2026 01:18 UTC | Zymeworks Inc. ZYME · Entity 4458 | Exercise / conversionCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-003095 · ownership.xml · nonDerivative · entry 3 Moore Paul Andrew · CIK 0001938192 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,212 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · price: Represents shares of common stock issued upon vesting of one third of the RSUs granted on January 5, 2024. Read SEC document |
| January 05, 2026 Filed Jan 6, 2026 01:18 UTC | Zymeworks Inc. ZYME · Entity 4458 | SaleCommon Stock | 9,289 | $25.10 | $233,125.10 |
DisclosureSEC source: 0001193125-26-003095 · ownership.xml · nonDerivative · entry 2 Moore Paul Andrew · CIK 0001938192 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,212 F2 · kind: Represents shares of common stock sold to cover tax withholding obligations and other applicable fees in connection with the vesting of RSUs pursuant to mandatory "sell to cover" provisions contained in the Reporting Person's applicable RSU grant agreement, and does not represent a discretionary sale by the Reporting Person. The Reporting Person did not sell or otherwise dispose of any of the shares reported on this Form 4 for any reason other than to cover required taxes and fees. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $24.715 to $25.84, inclusive. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| January 05, 2026 Filed Jan 6, 2026 01:18 UTC | Zymeworks Inc. ZYME · Entity 4458 | Exercise / conversionCommon Stock | 17,168 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-003095 · ownership.xml · nonDerivative · entry 1 Moore Paul Andrew · CIK 0001938192 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,501 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents shares of common stock issued upon vesting of one third of the restricted stock units ("RSUs") granted on January 5, 2023. Read SEC document |
| January 10, 2025 Filed Jan 10, 2025 23:07 UTC | Zymeworks Inc. ZYME · Entity 4458 | GrantRestricted Stock Unit · Derivative | 53,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-004352 · ownership.xml · derivative · entry 2 Moore Paul Andrew · CIK 0001938192 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,000 Underlying: Common Stock · 53,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting of the RSU, one share of Issuer's common stock. F3 · derivative.exercise_date: RSUs vest in three equal annual installments beginning on first anniversary of grant date. F3 · derivative.expiration_date: RSUs vest in three equal annual installments beginning on first anniversary of grant date. Read SEC document |
| January 10, 2025 Filed Jan 10, 2025 23:07 UTC | Zymeworks Inc. ZYME · Entity 4458 | GrantStock Option (Right to Buy) · Derivative | 79,000 | $0.00 Strike: $13.22 | $0.00 |
DisclosureSEC source: 0000950170-25-004352 · ownership.xml · derivative · entry 1 Moore Paul Andrew · CIK 0001938192 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,000 Underlying: Common Stock · 79,000 shares Expires 2035-01-09 F1 · derivative.exercise_date: Stock options vest as follows: (i) 25% of underlying shares of common stock on first anniversary of grant date and (ii) remainder of underlying shares of common stock in 36 equal monthly installments on last day of month following first anniversary of grant date. Read SEC document |
| January 06, 2025 Filed Jan 7, 2025 01:35 UTC | Zymeworks Inc. ZYME · Entity 4458 | Exercise / conversionRestricted Stock Unit · Derivative | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-002501 · ownership.xml · derivative · entry 6 Moore Paul Andrew · CIK 0001938192 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 20,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each RSU represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock. F7 · derivative.exercise_date: The RSUS were granted on January 5, 2024 and vest in three equal annual installments beginning on the first anniversary of January 5, 2024. F7 · derivative.expiration_date: The RSUS were granted on January 5, 2024 and vest in three equal annual installments beginning on the first anniversary of January 5, 2024. Read SEC document |
| January 06, 2025 Filed Jan 7, 2025 01:35 UTC | Zymeworks Inc. ZYME · Entity 4458 | Exercise / conversionRestricted Stock Unit · Derivative | 17,166 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-002501 · ownership.xml · derivative · entry 5 Moore Paul Andrew · CIK 0001938192 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,168 Underlying: Common Stock · 17,166 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each RSU represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock. F6 · derivative.exercise_date: The RSUS were granted on January 5, 2023 and vest in three equal annual installments beginning on the first anniversary of January 5, 2023. F6 · derivative.expiration_date: The RSUS were granted on January 5, 2023 and vest in three equal annual installments beginning on the first anniversary of January 5, 2023. Read SEC document |
| January 06, 2025 Filed Jan 7, 2025 01:35 UTC | Zymeworks Inc. ZYME · Entity 4458 | SaleCommon Stock | 11,408 | $14.92 | $170,254.13 |
DisclosureSEC source: 0000950170-25-002501 · ownership.xml · nonDerivative · entry 4 Moore Paul Andrew · CIK 0001938192 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,333 F2 · kind: Represents shares of common stock sold to cover tax withholding obligations and other applicable fees in connection with the vesting of RSUs pursuant to mandatory "sell to cover" provisions contained in the Reporting Person's applicable RSU grant agreement, and does not represent a discretionary sale by the Reporting Person. The Reporting Person did not sell or otherwise dispose of any of the shares reported on this Form 4 for any reason other than to cover required taxes and fees. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $14.44 to $15.14, inclusive. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| January 06, 2025 Filed Jan 7, 2025 01:35 UTC | Zymeworks Inc. ZYME · Entity 4458 | Exercise / conversionCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-002501 · ownership.xml · nonDerivative · entry 3 Moore Paul Andrew · CIK 0001938192 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,741 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · price: Represents shares of common stock issued upon vesting of one third of the RSUs granted on January 5, 2024. Read SEC document |
| January 06, 2025 Filed Jan 7, 2025 01:35 UTC | Zymeworks Inc. ZYME · Entity 4458 | SaleCommon Stock | 9,792 | $14.92 | $146,136.79 |
DisclosureSEC source: 0000950170-25-002501 · ownership.xml · nonDerivative · entry 2 Moore Paul Andrew · CIK 0001938192 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,741 F2 · kind: Represents shares of common stock sold to cover tax withholding obligations and other applicable fees in connection with the vesting of RSUs pursuant to mandatory "sell to cover" provisions contained in the Reporting Person's applicable RSU grant agreement, and does not represent a discretionary sale by the Reporting Person. The Reporting Person did not sell or otherwise dispose of any of the shares reported on this Form 4 for any reason other than to cover required taxes and fees. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $14.44 to $15.14, inclusive. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| January 06, 2025 Filed Jan 7, 2025 01:35 UTC | Zymeworks Inc. ZYME · Entity 4458 | Exercise / conversionCommon Stock | 17,166 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-002501 · ownership.xml · nonDerivative · entry 1 Moore Paul Andrew · CIK 0001938192 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,533 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents shares of common stock issued upon vesting of one third of the restricted stock units ("RSUs") granted on January 5, 2023. Read SEC document |
| January 08, 2024 Filed Jan 8, 2024 23:01 UTC | Zymeworks Inc. ZYME · Entity 4458 | SaleCommon Stock | 2,339 | $11.22 | $26,233.29 |
DisclosureSEC source: 0000950170-24-003076 · ownership.xml · nonDerivative · entry 3 Moore Paul Andrew · CIK 0001938192 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,367 F2 · kind: Represents shares of common stock sold to cover tax withholding obligations and other applicable fees in connection with the vesting of RSUs pursuant to mandatory "sell to cover" provisions contained in the Reporting Person's applicable RSU grant agreement, and does not represent a discretionary sale by the Reporting Person. The Reporting Person did not sell or otherwise dispose of any of the shares reported on this Form 4 for any reason other than to cover required taxes and fees. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $10.49 to $11.58, inclusive. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| January 05, 2024 Filed Jan 8, 2024 23:01 UTC | Zymeworks Inc. ZYME · Entity 4458 | GrantRestricted Stock Unit · Derivative | 60,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-003076 · ownership.xml · derivative · entry 6 Moore Paul Andrew · CIK 0001938192 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires not disclosed F5 · derivative.exercise_price: Each RSU represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock. F8 · derivative.exercise_date: The RSUs vest in three equal annual installments beginning on January 5, 2025. F8 · derivative.expiration_date: The RSUs vest in three equal annual installments beginning on January 5, 2025. Read SEC document |
| January 05, 2024 Filed Jan 8, 2024 23:01 UTC | Zymeworks Inc. ZYME · Entity 4458 | GrantStock Option (Right to Buy) · Derivative | 90,000 | $0.00 Strike: $10.56 | $0.00 |
DisclosureSEC source: 0000950170-24-003076 · ownership.xml · derivative · entry 5 Moore Paul Andrew · CIK 0001938192 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2034-01-04 F7 · derivative.exercise_date: Stock options vest as follows: (i) 25% of underlying shares of common stock on first anniversary of grant date and (ii) remainder of underlying shares of common stock in 36 equal monthly installments on last day of month following first anniversary of grant date. Read SEC document |
| January 05, 2024 Filed Jan 8, 2024 23:01 UTC | Zymeworks Inc. ZYME · Entity 4458 | Exercise / conversionRestricted Stock Unit · Derivative | 17,166 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-003076 · ownership.xml · derivative · entry 4 Moore Paul Andrew · CIK 0001938192 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,334 Underlying: Common Stock · 17,166 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each RSU represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock. F6 · derivative.exercise_date: The RSUS were granted on January 5, 2023 and vest in three equal annual installments beginning on January 5, 2024. F6 · derivative.expiration_date: The RSUS were granted on January 5, 2023 and vest in three equal annual installments beginning on January 5, 2024. Read SEC document |
| January 05, 2024 Filed Jan 8, 2024 23:01 UTC | Zymeworks Inc. ZYME · Entity 4458 | SaleCommon Stock | 7,460 | $10.65 | $79,465.41 |
DisclosureSEC source: 0000950170-24-003076 · ownership.xml · nonDerivative · entry 2 Moore Paul Andrew · CIK 0001938192 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,706 F2 · kind: Represents shares of common stock sold to cover tax withholding obligations and other applicable fees in connection with the vesting of RSUs pursuant to mandatory "sell to cover" provisions contained in the Reporting Person's applicable RSU grant agreement, and does not represent a discretionary sale by the Reporting Person. The Reporting Person did not sell or otherwise dispose of any of the shares reported on this Form 4 for any reason other than to cover required taxes and fees. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $10.55 to $10.845, inclusive. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| January 05, 2024 Filed Jan 8, 2024 23:01 UTC | Zymeworks Inc. ZYME · Entity 4458 | Exercise / conversionCommon Stock | 17,166 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-003076 · ownership.xml · nonDerivative · entry 1 Moore Paul Andrew · CIK 0001938192 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,166 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents shares of common stock issued upon vesting of one third of the restricted stock units ("RSUs") granted on January 5, 2023. Read SEC document |
| January 05, 2023 Filed Jan 7, 2023 01:00 UTC | Zymeworks Inc. ZYME · Entity 4458 | GrantRestricted Stock Unit · Derivative | 51,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-001216 · doc4.xml · derivative · entry 2 Moore Paul Andrew · CIK 0001938192 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,500 Underlying: Common Stock · 51,500 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock. F3 · derivative.exercise_date: The RSUs vest in three equal annual installments beginning on January 5, 2024. F3 · derivative.expiration_date: The RSUs vest in three equal annual installments beginning on January 5, 2024. Read SEC document |
| January 05, 2023 Filed Jan 7, 2023 01:00 UTC | Zymeworks Inc. ZYME · Entity 4458 | GrantStock Option (Right to Buy) · Derivative | 77,500 | $0.00 Strike: $8.00 | $0.00 |
DisclosureSEC source: 0000899243-23-001216 · doc4.xml · derivative · entry 1 Moore Paul Andrew · CIK 0001938192 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,500 Underlying: Common Stock · 77,500 shares Expires 2033-01-04 F1 · derivative.exercise_date: Stock options vest as follows: (i) 25% of underlying shares of common stock on first anniversary of grant date and (ii) remainder of underlying shares of common stock in 36 equal monthly installments on last day of month following first anniversary of grant date. Read SEC document |
| July 18, 2022 Filed Jul 19, 2022 21:05 UTC | Zymeworks BC Inc. ZYME · Entity 12038 | GrantStock Option (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $5.82 | $0.00 |
DisclosureSEC source: 0000899243-22-026386 · doc4.xml · derivative · entry 1 Moore Paul Andrew · CIK 0001938192 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Shares · 200,000 shares Expires 2032-07-17 F1 · derivative.exercise_date: Stock options vest as follows: (i) 25% of underlying shares on first anniversary of grant date and (ii) remainder of underlying shares in 36 equal monthly installments on last day of month following first anniversary of grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.